Cereno Scientific announced that an abstract on preclinical drug candidate CS585 has been accepted as an oral presentation by the Scientific Program Committee at the European Hematology Association (EHA) 2022 Hybrid Congress in Vienna, Austria, on June 9-12, 2022. The abstract: "CS585 is a first-in-class compound targeting the IP receptor for prevention of thrombosis without increased risk of bleeding" will be presented by Dr. Michael Holinstat, lead of Cereno's preclinical development programs at University of Michigan and Director of Translational Research at Cereno. The abstract titled "CS585 is a first-in-class compound targeting the IP receptor for prevention of thrombosis without increased risk of bleeding", was authored by Sylviane Lambert, Reheman Adili, Pooja Yalavarthi and Nicole Rhoads at Pharmacology, University of Michigan Medical School; Björn Dahlöf at Cereno Scientific and Institute of Medicine, University of Gothenburg; Andrew White at Medicinal Chemistry, University of Michigan Medical School; Niklas Bergh at Cereno Scientific and Institute of Medicine, University of Gothenburg; Michael Holinstat at Pharmacology and Internal Medicine, University of Michigan Medical School.

The abstract has been selected to be presented as an oral presentation by Dr. Michael Holinstat. The EHA2022 Hybrid Congress is organized by the European Hematology Association (EHA). The congress specializes in hematology and its subspecialties and, in particular, cutting-edge evidence-based approaches to diagnosis and treatment, highly anticipated clinical and translational research data, and newest developments in innovative techniques, diagnostic tools, and risk-assessment strategies.

The abstract will be published on May 12, 2022, at 16:00 CEST, in the online Abstract Book, a supplement of HemaSphere (EHA's official journal), the EHA Library and the Congress platform.